Filing Details
- Accession Number:
- 0001193125-23-204985
- Form Type:
- 13D Filing
- Publication Date:
- 2023-08-06 20:00:00
- Filed By:
- Deutsch Todd
- Company:
- Aim Immunotech Inc. (NYSEMKT:AIM)
- Filing Date:
- 2023-08-07
- SEC Url:
- 13D Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Todd Deutsch | 1,716,100 | 0 | 1,716,100 | 0 | 1,716,100 | 3.5% |
Ted D. Kellner | 394,000 | 1,049,000 | 394,000 | 1,049,000 | 1,443,000 | 3.0% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
AIM IMMUNOTECH INC.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
00901B105
(CUSIP Number)
Todd Deutsch
Ted D. Kellner
c/o Baker & Hostetler LLP
127 Public Square, Suite 2000
Cleveland, Ohio 44114
Attn: John J. Harrington
(216) 621-0200
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
August 4, 2023
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §240.13d-1(e), §240.13d-1(f) or §240.13d-1(g), check the following box: ☐
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13D
CUSIP No. 00901B105
1. | Names of Reporting Persons
Todd Deutsch | |||||
2. | Check the Appropriate Box if a Member of a Group (a) ☒ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
PF | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
United States of America |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
1,716,100 | ||||
8. | Shared Voting Power
0 | |||||
9. | Sole Dispositive Power
1,716,100 | |||||
10. | Shared Dispositive Power
0 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
1,716,100 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares
☒ | |||||
13. | Percent of Class Represented by Amount in Row (11)
3.5%(1) | |||||
14. | Type of Reporting Person
IN |
(1) | Percentage ownership based on 48,408,295 shares outstanding as reported in the Companys Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2023. |
CUSIP No. 00901B105
1. | Names of Reporting Persons
Ted D. Kellner | |||||
2. | Check the Appropriate Box if a Member of a Group (a) ☒ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
PF | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
United States of America |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
394,000 | ||||
8. | Shared Voting Power
1,049,000 | |||||
9. | Sole Dispositive Power
394,000 | |||||
10. | Shared Dispositive Power
1,049,000 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
1,443,000 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares
☒ | |||||
13. | Percent of Class Represented by Amount in Row (11)
3.0%(1) | |||||
14. | Type of Reporting Person
IN |
(1) | Percentage ownership based on 48,408,295 shares outstanding as reported in the Companys Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2023. |
SCHEDULE 13D
This Amendment No. 1 (Amendment No. 1) amends and supplements the Schedule 13D (the Initial Schedule 13D and together with this Amendment No. 1, the Schedule 13D) filed with the Securities and Exchange Commission on July 27, 2023 by Todd Deutsch and Ted D. Kellner (the Reporting Persons) with respect to the Common Stock, par value $0.001 per share, of AIM ImmunoTech Inc. (the Company). Capitalized terms used herein and not otherwise defined in this Amendment No. 1 shall have the meanings set forth in the Initial Schedule 13D. This Amendment No. 1 amends Item 4 to the extent set forth below.
Item 4. Purpose of the Transaction
Item 4 is hereby supplemented as follows:
In accordance with the requirements of the Companys bylaws, Mr. Kellner delivered on August 4, 2023 notice to the Company of his intent to nominate himself, Mr. Chioini and Mr. Deutsch for election to the Companys board of directors at the 2023 annual meeting of stockholders.
SIGNATURES
After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.
Date: August 7, 2023
TODD DEUTSCH | ||
By: | /s/ Todd Deutsch | |
TED D. KELLNER | ||
By: | /s/ Ted D. Kellner |